Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 232

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial

Chen, Yu-Pei, Liu, Xu, Zhou, Qin, Yang, Kun-Yu, Jin, Feng, Zhu, Xiao-Dong, Shi, Mei, Hu, Guo-Qing, Hu, Wei-Han, Sun, Yan, Wu, Hong-Fen, Wu, Hui, Lin, Qin, Wang, Hui, Tian, Ye, Zhang, Ning, Wang, Xi-Cheng, Shen, Liang-Fang, Liu, Zheng-Zheng, Huang, Jing, Luo, Xiu-Ling, Li, Ling, Zang, Jian, Mei, Qi, Zheng, Bao-Min, Yue, Dan, Xu, Jing, Wu, San-Gang, Shi, Yan-Xia, Mao, Yan-Ping, Chen, Lei, Li, Wen-Fei, Zhou, Guan-Qun, Sun, Rui, Guo, Rui, Zhang, Yuan, Xu, Cheng, Lv, Jia-Wei, Guo, Ying, Feng, Hui-Xia, Tang, Ling-Long, Xie, Fang-Yun, Sun, Ying, Ma, Jun·2021·The Lancet

Abstract

BACKGROUND Patients with locoregionally advanced nasopharyngeal carcinoma have a high risk of disease relapse, despite a high proportion of patients attaining complete clinical remission after receiving standard-of-care treatment (ie, definitive concurrent chemoradiotherapy with or without induction chemotherapy). Additional adjuvant therapies are needed to further reduce the risk of recurrence and death. However, the benefit of adjuvant chemotherapy for nasopharyngeal carcinoma remains controversial, highlighting the need for more effective adjuvant treatment options. METHODS This multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial was done at 14 hospitals in China. Patients (aged 18-65 years) with histologically confirmed, high-risk locoregionally advanced nasopharyngeal carcinoma (stage III-IVA, excluding T3-4N0 and T3N1 disease), no locoregional disease or distant metastasis after definitive chemoradiotherapy, an Eastern Cooperative Oncology Group performance status of 0 or 1, sufficient haematological, renal, and hepatic function, and who had received their final radiotherapy dose 12-16 weeks before randomisation, were randomly assigned (1:1) to receive either oral metronomic capecitabine (650 mg/m2 body surface area twice daily for 1 year; metronomic capecitabine group) or observation (standard therapy group). Randomisation was done with a computer-generated sequence (block size of four), stratified by trial centre and receipt of induction chemotherapy (yes or no). The primary endpoint was failure-free survival, defined as the time from randomisation to disease recurrence (distant metastasis or locoregional recurrence) or death due to any cause, in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of capecitabine or who had commenced observation. This trial is registered with ClinicalTrials.gov, NCT02958111. FINDINGS Between Jan 25, 2017, and Oct 25, 2018, 675 patients were screened, of whom 406 were enrolled and randomly assigned to the metronomic capecitabine group (n=204) or to the standard therapy group (n=202). After a median follow-up of 38 months (IQR 33-42), there were 29 (14%) events of recurrence or death in the metronomic capecitabine group and 53 (26%) events of recurrence or death in the standard therapy group. Failure-free survival at 3 years was significantly higher in the metronomic capecitabine group (85·3% [95% CI 80·4-90·6]) than in the standard therapy group (75·7% [69·9-81·9]), with a stratified hazard ratio of 0·50 (95% CI 0·32-0·79; p=0·0023). Grade 3 adverse events were reported in 35 (17%) of 201 patients in the metronomic capecitabine group and in 11 (6%) of 200 patients in the standard therapy group; hand-foot syndrome was the most common adverse event related to capecitabine (18 [9%] patients had grade 3 hand-foot syndrome). One (<1%) patient in the metronomic capecitabine group had grade 4 neutropenia. No treatment-related deaths were reported in either group. INTERPRETATION The addition of metronomic adjuvant capecitabine to chemoradiotherapy significantly improved failure-free survival in patients with high-risk locoregionally advanced nasopharyngeal carcinoma, with a manageable safety profile. These results support a potential role for metronomic chemotherapy as an adjuvant therapy in the treatment of nasopharyngeal carcinoma. FUNDING The National Natural Science Foundation of China, the Key-Area Research and Development Program of Guangdong Province, the Natural Science Foundation of Guangdong Province, the Innovation Team Development Plan of the Ministry of Education, and the Overseas Expertise Introduction Project for Discipline Innovation. TRANSLATION For the Chinese translation of the abstract see Supplementary Materials section.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(21)01123-5

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 232

Metadata

Authors
Chen, Y.-P., Liu, X., Zhou, Q., Yang, K.-Y., Jin, F., Zhu, X.-D., Shi, M., Hu, G.-Q., Hu, W.-H., Sun, Y., Wu, H.-F., Wu, H., Lin, Q., Wang, H., Tian, Y., Zhang, N., Wang, X.-C., Shen, L.-F., Liu, Z.-Z., Huang, J., Luo, X.-L., Li, L., Zang, J., Mei, Q., Zheng, B.-M., Yue, D., Xu, J., Wu, S.-G., Shi, Y.-X., Mao, Y.-P., Chen, L., Li, W.-F., Zhou, G.-Q., Sun, R., Guo, R., Zhang, Y., Xu, C., Lv, J.-W., Guo, Y., Feng, H.-X., Tang, L.-L., Xie, F.-Y., Sun, Y., & Ma, J.
Venue
The Lancet
Publisher
Elsevier BV
Published
2021-07
Volume
398
Issue
10297
Pages
303-313
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W3172428308
Cited by
232
References
1
FWCI
28.70
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(21)01123-5
The paper
Chen, Y.-P., Liu, X., Zhou, Q., Yang, K.-Y., Jin, F., Zhu, X.-D., Shi, M., Hu, G.-Q., Hu, W.-H., Sun, Y., Wu, H.-F., Wu, H., Lin, Q., Wang, H., Tian, Y., Zhang, N., Wang, X.-C., Shen, L.-F., Liu, Z.-Z., . . . Ma, J. (2021). Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(21)01123-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.